{"slug":"cardiogen","seoKey":"cardiogen","displayName":"Cardiogen","codes":["AEDR","АКС-К"],"synonyms":["Ala-Glu-Asp-Arg","H-Ala-Glu-Asp-Arg-OH","AEDR peptide","alanyl-glutamyl-aspartyl-arginine","L-alanyl-L-glutamyl-L-aspartyl-L-arginine","Kardiogen / Кардиоген (Russian trade name)"],"legalClass":"research_chemical","identifiers":{"formula":"C18H31N7O9","molecularWeight":489.48,"sequence":"AEDR"},"approvals":[{"market":"US","status":"not_approved","note":"The peptide is not approved and is not held as a substance identity in any federal database. There is no drug label for the tetrapeptide, and the substance registration system returns no exact name match for alanyl-glutamyl-aspartyl-arginine, which is why there is no UNII. Name collision, checked on 2026-09-20 and stated here because it is routinely misread as an approval: the single label, the single Drugs@FDA entry and all 127 adverse event reports carrying the string CardioGen belong to CardioGen-82, a rubidium-82 generator for PET myocardial perfusion imaging from Bracco Diagnostics, approved under NDA 019414 with rubidium chloride Rb-82 as its active substance. That product is a radiopharmaceutical and is not this peptide. The substance has also never been nominated for the compounding bulks list; the dipeptide alanyl-L-glutamine sits in category 1, so short peptides are covered in principle and this is an absence, not an oversight.","source":"https://api.fda.gov/drug/label.json?search=openfda.substance_name:%22CARDIOGEN%22"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report and no withdrawal document. The register itself could not be queried on 2026-09-20 because the full-text search returned an authorisation error, so this is a negative finding drawn from the absence of any entry in every other authority database checked and from the absence of any clinical development programme at all. No novel food authorisation is known either, and that catalogue could not be queried: the portal is a JavaScript application that returned only its own page shell.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=cardiogen"},{"market":"DE","status":"not_approved","note":"Neither a national nor an EU marketing authorisation exists, so an injectable preparation is not a marketable medicinal product and may not be imported or dispensed. The substance is also not named in the schedule to the Anti-Doping Act: the full text was checked on 2026-09-20 for the trade name, the transliteration, the sequence and the code without a hit, and that schedule lists its peptide hormones, growth factors and mimetics by name with no catch-all position under which a cardiac tetrapeptide would fall. Sporting rules are unaffected by that.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The product register returned only the JavaScript shell of its search page on 2026-09-20, with the result list loaded client-side, so the negative finding could not be verified positively. It rests on the absence of any entry in every register that could be queried and on the absence of any clinical development.","source":"https://products.mhra.gov.uk/search/?search=cardiogen"},{"market":"AU","status":"not_approved","note":"Not named in the Poisons Standard; the full text of the June 2026 instrument was searched on 2026-09-20 for the trade name, the transliteration, the sequence and the code without a hit. There is no generic peptide position in that instrument, and short peptides are listed by name where they are scheduled, so this is a real absence — the control search for alanylglutamine returns two hits. Absence of a listing is not a clearance: an injectable preparation not entered in the goods register may not be supplied, and that register was not reachable on the day of checking.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no entry in the drug product database, for the peptide or for the identically named radiopharmaceutical; queries for both brand spellings returned empty results on 2026-09-20, while a control query for an authorised product returned its identification number, so the interface was working.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=cardiogen"},{"market":"CH","status":"not_approved","note":"The peptide is not authorised. The official list of authorised human medicines (state of 2026-08-31) was downloaded and searched in full on 2026-09-20, and this is the point where the name trap must be stated plainly: the one and only match for CardioGen is authorisation number 62332, Cardiogen-82, generatore di radionuclidi, holder Bracco Suisse SA, category radiopharmaceuticals, supply category A. That is the rubidium-82 generator, not the tetrapeptide. Searches for alanyl and for the transliteration kardiogen return nothing, while control searches for two authorised semaglutide products return five and ten entries, so the list and the search were complete and working.","source":"https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":[],"lastVerified":"2026-09-20","version":"1.0","published":true,"locale":"en","title":"Cardiogen: what the studies show, status and safety","summary":"Cardiogen is a synthetic chain of four amino acids from a St Petersburg institute, sold as a heart peptide. Every finding about a living heart comes from a patent application from 2004 that was never published in a journal, and no study in people exists. It is approved as a medicine nowhere. The approved product called CardioGen-82 is a radioactive generator for heart imaging and a different thing entirely.","updated":"2026-09-20","url":"https://mypep.app/peptides/cardiogen"}